Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Biocept, Inc. (BIOCQ)
San Diego, CA, US
Biocept, Inc., established in 1997 and based in San Diego, California, was a molecular oncology diagnostics firm. Its primary business involved the development and commercialization of exclusive clinical laboratory assays within the United States. These advanced tests were engineered to detect elusive tumor cells and cell-free tumor DNA (ctDNA) from both blood and cerebrospinal fluid (CSF) samples. The insights provided by Biocept's cancer assays were instrumental for healthcare professionals, allowing them to pinpoint specific cancer-causing genetic mutations. This capability helped identify suitable cancer patients for targeted therapies, whether at the point of initial diagnosis, during disease progression, or for continuous monitoring to uncover resistance mechanisms. The company offered diagnostic solutions for a variety of solid tumor cancers, such as breast, non-small cell lung (NSCLC), gastric, colorectal, prostate, pancreaticobiliary, and ovarian cancers. Furthermore, Biocept extended specialized testing services for CSF tumor cells, ctDNA, and ctRNA to a diverse group of medical specialists, including medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, and pathologists. It also supplied clinical trial and research assistance to pharmaceutical and biopharmaceutical companies, along with clinical research organizations. Biocept participated in collaborations, notably with CLEARED4 to create a system for overseeing COVID-19 testing requirements and results for its clientele. Another partnership with Protean BioDiagnostics, Inc. aimed to evaluate the proficiency of its Target Selector molecular assay in ascertaining EGFR status in NSCLC patients. However, Biocept, Inc. voluntarily initiated liquidation proceedings by filing for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware on October 13, 2023.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -90.00% | +0.00% | +0.00% | +0.00% | +0.00% | -100.00% | -100.00% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%-57.8%
-
EPS growth Medical - Diagnostics & Research: +30.8%-890.9%
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-69.4% Q2'23: -540.4%
-
EBIT margin Medical - Diagnostics & Research: +9.6%-123.4% Q2'23: -608.0%
-
ROIC Medical - Diagnostics & Research: +5.2%-395.1% Q2'23: -272.9%
-
Share dilution Medical - Diagnostics & Research: 0.0%+14.7%
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-0.40× Q2'23: -0.99×
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
671.0K
est.
|
3.17M
est.
|
5.25M
est.
|
3.28M
est.
|
5.53M
est: 5.44M (+1.6%)
|
27.46M
est: 13.41M (+104.7%)
|
61.25M
est: 61.20M (+0.1%)
|
25.86M
est: 39.41M (-34.4%)
|
2.48M
est.
|
5.47M
est.
|
18.98M
est.
|
44.91M
44.91M – 44.91M
+136.6% YoY
|
90.18M
90.18M – 90.18M
+100.8% YoY
|
| EBITDA |
-439.1K
est.
|
-2.08M
est.
|
-3.44M
est.
|
-2.14M
est.
|
-24.11M
est: -3.56M (-576.9%)
|
-16.57M
est: -8.78M (-88.8%)
|
-879.0K
est: -40.05M (+97.8%)
|
-30.24M
est: -25.79M (-17.3%)
|
-1.62M
est.
|
-3.58M
est.
|
-12.42M
est.
|
-29.39M
-29.39M – -29.39M
-136.6% YoY
|
-59.01M
-59.01M – -59.01M
-100.8% YoY
|
| EBIT |
-449.4K
est.
|
-2.12M
est.
|
-3.52M
est.
|
-2.19M
est.
|
-24.89M
est: -3.65M (-582.6%)
|
-17.57M
est: -8.98M (-95.6%)
|
-2.41M
est: -40.99M (+94.1%)
|
-31.90M
est: -26.40M (-20.8%)
|
-1.66M
est.
|
-3.67M
est.
|
-12.71M
est.
|
-30.08M
-30.08M – -30.08M
-136.6% YoY
|
-60.40M
-60.40M – -60.40M
-100.8% YoY
|
| Net Income |
-15.95B
est.
|
-10.96B
est.
|
-3.87B
est.
|
-1.58B
est.
|
-25.14M
est: -162.76M (+84.6%)
|
-17.81M
est: -19.50M (+8.7%)
|
-2.82M
est: -2.03M (-38.8%)
|
-32.09M
est: -17.72M (-81.1%)
|
-2.96M
est.
|
-779.9K
est.
|
-480.4K
est.
|
-56.5K
-56.5K – -56.5K
+88.2% YoY
|
909.9K
909.9K – 909.9K
+1,710.0% YoY
|
| SGA |
699.9K
est.
|
3.31M
est.
|
5.48M
est.
|
3.42M
est.
|
12.91M
est: 5.68M (+127.4%)
|
16.37M
est: 13.99M (+17.0%)
|
20.93M
est: 63.83M (-67.2%)
|
23.24M
est: 41.10M (-43.5%)
|
2.58M
est.
|
5.71M
est.
|
19.79M
est.
|
46.84M
46.84M – 46.84M
+136.6% YoY
|
94.06M
94.06M – 94.06M
+100.8% YoY
|
| EPS |
-28,215.00
est.
|
-19,395.00
est.
|
-6,840.00
est.
|
-2,803.50
est.
|
-365.01
est: -288.00 (-26.7%)
|
-45.10
est: -34.50 (-30.7%)
|
-5.73
est: -3.60 (-59.2%)
|
-56.78
est: -31.35 (-81.1%)
|
-5.24
est.
|
-1.38
est.
|
-0.85
est.
|
-0.10
-0.10 – -0.10
+88.2% YoY
|
1.61
1.61 – 1.61
+1,710.0% YoY
|
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Empery Asset Management, LP | 2.31M | 4.99% | — | 2.31M | — | — | PN | Delaware | 2020-01-15 | ↗ |
| 2 | Martin D. Hoe | 2.31M | 4.99% | — | 2.31M | — | — | IN | United States | 2020-01-15 | ↗ |
| 3 | Ryan M. Lane | 2.31M | 4.99% | — | 2.31M | — | — | IN | United States | 2020-01-15 | ↗ |
| 4 | B. Asher | 1.97M | 4.50% | — | 1.97M | — | 1.97M | HC, IN | States of America | 2020-02-11 | ↗ |
| 5 | Intracoastal Capital LLC | 1.97M | 4.50% | — | 1.97M | — | 1.97M | OO | Delaware | 2020-02-11 | ↗ |
| 6 | P. Kopin | 1.97M | 4.50% | — | 1.97M | — | 1.97M | HC | United States of America | 2020-02-11 | ↗ |
| 7 | Capital LLC | 1.34M | 9.99% | — | 1.34M | — | 1.34M | OO | Delaware | 2019-02-19 | ↗ |
| 8 | 1,262,573 (see Item 4) | 1.26M | 12.00% | — | 1.26M | — | 1.26M | HC, IN | United States of America | 2016-05-06 | ↗ |
| 9 | 13G | 1.19M | 9.90% | — | 1.19M | — | 1.19M | IN | Texas | 2019-02-19 | ↗ |
| 10 | 1,137,921 | 1.14M | 12.00% | — | 1.14M | — | 1.14M | HC, OO | Alaska | 2016-10-24 | ↗ |
| 11 | 1,129,321 | 1.13M | 12.00% | — | 1.13M | — | 1.13M | PN | Alaska | 2016-10-24 | ↗ |
| 12 | Alex Noah Investors, Inc. | 394.3K | 9.99% | — | 394.3K | — | 394.3K | CO | Illinois | 2018-09-24 | ↗ |
| 13 | Jonathan I. Cope | 394.3K | 9.99% | — | 394.3K | — | 394.3K | IN | United States | 2018-09-24 | ↗ |
| 14 | Joshua B. Scheinfeld | 394.3K | 9.99% | — | 394.3K | — | 394.3K | IN | United States | 2018-09-24 | ↗ |
| 15 | Lincoln Park Capital Fund, LLC | 394.3K | 9.99% | — | 394.3K | — | 394.3K | OO | Illinois | 2018-09-24 | ↗ |
| 16 | Lincoln Park Capital, LLC | 394.3K | 9.99% | — | 394.3K | — | 394.3K | OO | Illinois | 2018-09-24 | ↗ |
| 17 | Rockledge Capital Corporation | 394.3K | 9.99% | — | 394.3K | — | 394.3K | CO | Texas | 2018-09-24 | ↗ |
| 18 | Jeff Easton | 147.3K | 9.90% | 147.3K | — | 147.3K | — | IN | United States | 2023-06-02 | ↗ |
| 19 | Lind Global Fund II LP | 147.3K | 9.90% | 147.3K | — | 147.3K | — | PN | Delaware | 2023-06-02 | ↗ |
| 20 | Lind Global Partners II LLC | 147.3K | 9.90% | 147.3K | — | 147.3K | — | OO | Delaware | 2023-06-02 | ↗ |
| 21 | Daniel B. Asher | 132.3K | 3.40% | — | 132.3K | — | 132.3K | HC | States of America | 2019-02-08 | ↗ |
| 22 | Mitchell P. Kopin | 132.3K | 3.40% | — | 132.3K | — | 132.3K | HC | States of America | 2019-02-08 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Veena Singh | Senior Medical Director | 361.0K | — |
| Pavel Tsinberg | Director of Technology Development | — | male |
| Soon Kap Hahn | Founder | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BIOCQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
